Drug Approved to Fight Rare Cancer That Hits Young Adults

Follow Drugslib on

Medically reviewed by Drugs.com.

By Dennis Thompson HealthDay Reporter

WEDNESDAY, Aug. 7, 2024 -- A new immunotherapy is now available to treat a rare soft tissue cancer that most frequently occurs in young men.

The U.S. Food and Drug Administration has granted accelerated approval to Tecelra (afamitresgene autoleuecel) to treat synovial sarcoma, which most commonly develops in the muscles and ligaments of the arms and legs.

Tecelra is the first lab-engineered immune cell therapy to receive FDA approval for a solid tumor cancer, the researchers noted. It’s made by Adaptimmune, a pharmaceutical company located in Philadelphia, which funded the clinical trials that led to approval.

“This treatment offers an important new option for people with this rare cancer,” said lead researcher Dr. Sandra D’Angelo, a sarcoma specialist and immunotherapy expert with Memorial Sloan Kettering Cancer Center in New York City. “It is also an important step forward in the development of T-cell therapies for solid tumors, which has been a major challenge.”

Synovial sarcoma is diagnosed in fewer than 1,000 people in the United States every year, the FDA said. It most often occurs in men in their 30s or younger.

Up to now, treatment has typically involved surgery to remove the tumor, followed by radiation or chemotherapy.

“Sarcoma in general, and synovial sarcoma in particular, is a type of cancer where more treatments are desperately needed,” D’Angelo said in a Sloan Kettering news release. “Once the disease spreads to other parts of the body, it is very difficult to control with the therapies we have now.”

The treatment involves using a person’s own immune cells, which are extracted from their bodies and genetically modified to better detect and attack cancer cells.

The approval was based on clinical trial results in 52 people with either synovial sarcoma or myxoid/round cell liposarcoma (MRCLS), another type of soft tissue sarcoma. None of the patients had responded to other therapies.

Nearly 37% of patients saw their tumors shrink after a single dose of Tecelra, results show.

Overall, the drug helped about 39% of people with synovial sarcoma and 25% of those with MRCLS.

Patients with synovial sarcoma responded to the therapy for an average of 11.6 months, results show.

“These findings are significant for a group of patients who have largely exhausted other treatment options,” D’Angelo said.

About 71% of patients experienced cytokine release syndrome, which occurs when the immune system temporarily goes into overdrive to fight cancer. The syndrome was not severe in most patients, researchers said.

“Adults with metastatic synovial sarcoma, a life-threatening form of cancer, often face limited treatment options in addition to the risk of cancer spread or recurrence,” Dr. Nicole Verdun, director of the Office of Therapeutic Products in the FDA’s Center for Biologics Evaluation and Research, said in an agency news release. “Today’s approval represents a significant milestone in the development of an innovative, safe and effective therapy for patients with this rare but potentially fatal disease.”

Sources

  • Memorial Sloan Kettering Cancer Center, news release, Aug. 2, 2024
  • U.S. Food and Drug Administration, news release, Aug. 2, 2024

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2024-08-07 23:15

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords